FDA warns over Diet Coke Plus nutrition claims

By Susan Heavey

WASHINGTON (Reuters) - Coca-Cola Co’s claims that its Diet Coke Plus include a variety of vitamins and minerals does not meet U.S. Food and Drug Administration’s standards, the agency said in a warning to the company.

“The FDA does not consider it appropriate to fortify snack foods such as carbonated beverages,” the agency said in a December 10 letter to the beverage giant released on Tuesday.

Additionally, the product’s label does not include the additional amounts of nutrients included in the “plus” product as the agency requires, the letter said.

Representatives for Coca-Cola defended the product’s claims.

“This does not involve any health or safety issues, and we believe the label on Diet Coke Plus complies with FDA’s policies and regulations,” company spokesman Scott Williamson told Reuters.

Coca-Cola has marketed Diet Coke Plus as “a good source of vitamins B3, B6, and B12, and the minerals zinc and magnesium.” It was launched in the United States in April 2007.

It is part of its Diet Coke line of products, the calorie-free alternative to regular Coca-Cola beverages.

The company has 15 days to outline plans to correct the violation, and Coca-Cola’s Williamson said it would reply to the FDA letter in early January.

FDA officials issue dozens of similar warning letters each year, and most are resolved without further issues. But the agency can take stronger action if necessary, including levying fines and seizing products.

The FDA released the warning letter on its website here (Reporting by Susan Heavey; additional reporting by Aarthi Sivaraman in New York; editing by Jeffrey Benkoe)

Source

--------------------------------------------------------------------------------------------
Related Posts:


WASHINGTON (Reuters) - A U.S. consumer group said Thursday it filed a class action lawsuit against Coca-Cola Co, accusing the company of making deceptive health claims about its VitaminWater beverages. The Center for Science in the Public Interest (CSPI) said Coke made a range of claims that go beyond those allowed by the Food and Drug

Full Post: U.S. group sues Coke over VitaminWater health claims
--------------------------------------------------------------------------------------------

WASHINGTON (Reuters) - An advertisement for Abbott Laboratories’ Humira minimizes the arthritis drug’s risks while suggesting it can treat a wider range of patients than it is approved to treat, the U.S. Food and Drug Administration said in a letter released on Tuesday. The drug is cleared to treat certain patients with arthritis, psoriasis, Crohn’s Disease

Full Post: FDA says ad for Abbott’s Humira downplays risks
--------------------------------------------------------------------------------------------

By Susan Heavey WASHINGTON (Reuters) - Democratic lawmakers are expanding a probe into direct-to-consumer drug advertisements to include Bayer AG’s combination aspirin product, according to letters released on Tuesday. Bayer’s marketing of its Aspirin with Heart Advantage, a combination product that includes a dietary supplement, appears to go against a U.S. Food and Drug Administration request not

Full Post: Lawmakers question ads for Bayer “herbal” aspirin
--------------------------------------------------------------------------------------------

NEW YORK (Reuters) - New data do not signal any heart risks with Takeda Pharmaceutical Co Ltd’s experimental drug to treat acid build-up in patients with gout, a top U.S. Food and Drug Administration official said in a document released on Thursday. Takeda is seeking U.S. approval to sell its drug febuxostat for chronic gout patients

Full Post: No heart risk seen with Takeda gout drug: FDA
--------------------------------------------------------------------------------------------

By Susan Heavey WASHINGTON (Reuters) - Data show Novartis AG’s combination malaria drug Coartem appears to work and causes few serious side effects, U.S. Food and Drug Administration regulatory staff said in documents released on Monday. “The majority of AEs (adverse events) were of mild or moderate intensity. Deaths … and SAEs (serious adverse events) … were

Full Post: Novartis malaria drug safe, effective: FDA

Site Navigation

Most Read

Search